Allergan, Inc.

Icon Bioscience, Inc.

Chibi, Inc.

Ramscor, Inc.

Glenn T Huang

Vernon G Wong

Thierry Nivaggioli

Patrick Michael Hughes

Larry Allen Wheeler

James A Burke

Ton Lin

Rosy Sheng Donn

Mae W Hu

Kai-Ming Zhang

Brittany A Jackson

James Nienyuan Chang

Orest Olejnik

Lon T Spada

Hiroshi Sugimoto

Wendy M Blanda

William S White

Tan Pham

Faina Karasina

Louis L Wood

Rosy Sheng

Orilla C Werhner

Maria Escobar

Louis Wood

The present embodiments provide compositions, methods, and kits for the treatment or prevention of ocular conditions or maladies via non-invasive liquid depots. In at least one embodiment, the liquid depot is capable of sustained-release delivery of at least one pharmaceutical agent to the eye for days or weeks.

Liquid depot for non-invasive sustained delivery of agents to the eye

The present embodiments provide compositions, methods and kits for the treatment of ocular conditions or maladies affecting the back of the eye, e.g., the retina.

Eye drop formulation and method for sustained delivery of medicament to the retina

The present embodiments provide for simple devices that guide the loading and dispensing of accurate small doses of fluid from standard injection syringes.

Dose guides for injection syringe

Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, among others.

Sustained release intraocular implants and methods for treating ocular vasculopathies

The present embodiments provide for a treatment regimen and use of a short-term sustained release liquid formulation of dexamethasone in citrate, wherein a single administration of a minute dosage form into the anterior chamber of the eye provides for anti-inflammatory therapy following cataract surgery.

Use of sustained release dexamethasone in post-cataract surgery inflammation

Devices that guide the accurate loading and dispensing of predetermined doses of fluid from injection syringes are disclosed.

The present invention provides for injectable pharmaceutical sustained release formulations for delivery of active agents, particularly therapeutic proteins, to the eye. The formulations are biocompatible, biodegradable sustained release formulations comprising low-solubility liquid excipients and relatively small amounts (less than about 10%) of biocompatible, biodegradable polymer such as PLA or PLGA polymers. A unit dose of 5 &#x3bc;L to 100 &#x3bc;L of the formulation provides for sustained release of the agent for at least 14 days.

Sustained release formulations for delivery of proteins to the eye and methods of preparing same

The present embodiments provide for methods of treating elevated intraocular pressure or glaucoma using a sustained release medicament consisting of prostaglandin in benzyl benzoate that is injected intraocularly no more frequently than once every two months.

Sustained release formulations for the treatment of intraocular pressure or glaucoma

Biocompatible intraocular implants include a steroid and an auxiliary agent, where the auxiliary agent is present in an amount sufficient to lessen the severity of at least one side effect compared to the use of an otherwise identical implant lacking said auxiliary agent. The steroid and the auxiliary agent may be present on the same intraocular implant or on different implants. The steroid and auxiliary agent may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the steroid may be associated with a polymeric coating having one or more openings effective to permit the steroid to be released into an external environment. The implants containing the steroid and an auxiliary agent may be placed in an eye to treat one or more ocular conditions while reducing the side effects otherwise accompanying steroid use.

Steroid-containing sustained release intraocular implants and related methods

Sustained release formulations for the treatment of intraocular pressure of glaucoma

Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to prevent the occurrence of one or more ocular conditions, or to reduce one or more symptoms of an ocular condition, such as an ocular neurosensory disorder and the like.

Growing community of inventors

Fremont, CA, United States of America

Glenn T Huang